If you’ve seen an unusual number of pink ribbons lately, you already know that October is Breast Cancer Awareness Month. We’re taking the opportunity to celebrate the amazing advances that our customers are making in understanding breast cancer.
We can’t possibly cover all the great projects here, but these examples illustrate some of the important findings that scientists have made:
- In this paper, scientists in Korea analyzed variants of unknown significance in BRCA1 and BRCA2 across more than 700 breast cancer patients. They used HGMD and reported outcomes that could have significant impact on how genetic counseling is conducted for patients with breast cancer.
- Another publication from scientists in Romania used Ingenuity Pathway Analysis to find the biological pathways and processes disrupted by gene expression changes in people with triple-negative breast cancer. The project shows promise for the use of immunotherapy for patients with this difficult diagnosis.
- This case story about Milan Radovich, a scientist at the Indiana University School of Medicine, describes his in-depth examination of pathways in triple-negative breast cancer. He uses IPA and Ingenuity Variant Analysis for this and other work. One of his studies determined for the first time that breast tissue from healthy patients serves as a better control than adjacent normal tissue taken from breast cancer patients.
To learn more about how our tools can be used for these kinds of studies, you can check out the application note entitled "Understanding breast cancer subtypes by jointly interpreting tumor genomes and transcriptomes".
And don’t miss our webinar on Thursday, October 20, which will offer a presentation on how QIAGEN Clinical Insight (QCI) Interpret can be used to support decisions about which targeted therapy to use for breast cancer patients.
HGMD: Gain a comprehensive view of predisposing mutations
Support for breast cancer research and breast cancer patients worldwide
